Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Free Cash Flow (2016 - 2025)

Guided Therapeutics' Free Cash Flow history spans 15 years, with the latest figure at -$277000.0 for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 41.44% year-over-year to -$277000.0; the TTM value through Sep 2025 reached -$1.1 million, up 1.25%, while the annual FY2024 figure was -$1.1 million, 35.91% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$277000.0 at Guided Therapeutics, down from -$169000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $155000.0 in Q4 2021 and bottomed at -$744000.0 in Q3 2021.
  • The 5-year median for Free Cash Flow is -$336000.0 (2023), against an average of -$355684.2.
  • The largest annual shift saw Free Cash Flow surged 146.83% in 2021 before it plummeted 320.65% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at $155000.0 in 2021, then tumbled by 320.65% to -$342000.0 in 2022, then grew by 1.75% to -$336000.0 in 2023, then grew by 1.19% to -$332000.0 in 2024, then rose by 16.57% to -$277000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Free Cash Flow are -$277000.0 (Q3 2025), -$169000.0 (Q2 2025), and -$331000.0 (Q1 2025).